Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
SAN DIEGO, April 27, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 11, 2017 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 15172159
Prior to the webcast at approximately 4:30 PM Eastern Time on May 11, Cytori will issue its first quarter earnings release which will review Cytori’s first quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao, 1.858.458.0900 [email protected]
